Bitte beachten Sie: Suchbegriffe unter einer Länge von 3 Buchstaben werden ignoriert.
267 Treffer:
51.
Phase I Open-label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination With an Anti-PD-1 mAb in Patients With Advanced or Metastatic Solid Tumors
NCT Heidelberg » Für Ärzte » Studien » Gastrointestinale Tumoren » Pankreaskarzinom
Datum: 2026-04-04
52.
Comprehensive assesment of clinical features, genomics and further molecular marker to identify patients with early breast cancer for enrolment on marker driven trials
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Mammakarzinom
Datum: 2026-04-04
53.
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion
NCT Heidelberg » Für Ärzte » Studien » Gastrointestinale Tumoren » Pankreaskarzinom
Datum: 2026-04-04
54.
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Mammakarzinom
Datum: 2026-04-04
55.
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Mammakarzinom
Datum: 2026-04-04
56.
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Mammakarzinom
Datum: 2026-04-04
57.
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination With Other Anticancer Therapies in Solid Tumors
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Mammakarzinom
Datum: 2026-04-04
58.
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute M
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Akute myeloische Leukämie
Datum: 2026-04-04
59.
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Multiples Myelom
Datum: 2026-04-04
60.
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors
NCT Heidelberg » Für Ärzte » Studien » Entitätenübergreifend/Basket
Datum: 2026-04-04